A nurse is reviewing the medical record of a client who is prescribed interferon alfa-2b. Which condition should the nurse recognize as an indication for this medication?

A. Type 1 diabetes is an autoimmune disease in which the body’s immune system attacks the insulin-producing beta cells in the pancreas, leading to insulin deficiency. Interferon alfa-2b is not indicated for type 1 diabetes because it does not replace insulin, prevent autoimmune beta-cell destruction, or manage blood glucose levels. Medications for type 1 diabetes focus on insulin therapy, glucose monitoring, and lifestyle management. Administering interferon in this context would have no therapeutic benefit and could cause unnecessary side effects such as flu-like symptoms or hematologic changes. B. Chronic hepatitis B is a viral infection of the liver caused by the hepatitis B virus (HBV). Interferon alfa-2b is a type of immunomodulator that enhances the body’s immune response to viral infections. It works by binding to cell surface receptors and inducing antiviral proteins that inhibit viral replication, helping to reduce the viral load in the liver. Interferon therapy can slow disease progression, reduce liver inflammation, and decrease the risk of cirrhosis or hepatocellular carcinoma. It is an approved first-line therapy for chronic hepatitis B in certain patients, especially those with evidence of active viral replication and elevated liver enzymes. C. Osteoarthritis is a degenerative joint disease caused by the breakdown of cartilage, resulting in pain, stiffness, and limited mobility. Interferon alfa-2b has no role in treating osteoarthritis because it does not affect cartilage regeneration, inflammation in the joints, or pain control. Management of osteoarthritis includes non-pharmacologic measures (exercise, weight management, physical therapy), pharmacologic therapy (NSAIDs, acetaminophen), and in some cases surgical interventions (joint replacement). D. COPD is a chronic inflammatory lung disease, usually caused by smoking, that leads to airflow obstruction and difficulty breathing. Interferon alfa-2b is not used for COPD because the disease is not viral in origin and does not involve immune-mediated viral replication. Treatment focuses on bronchodilators, corticosteroids, oxygen therapy, pulmonary rehabilitation, and smoking cessation. Using interferon would not provide therapeutic benefit and could potentially worsen side effects such as flu-like symptoms or hematologic abnormalities.